Ai-Min Hui

MRNA COVID-19 vaccine: in late January 2020, Dr. Hui initiated and led the deal finding, contract agreement signing, and the joint research/development, registration and launch of mRNA COVID-19 vaccine BNT162b2 in Greater China (named as FUBITAI, a.k.a. Comirnaty® outside of China) between BioNTech and Fosun Pharma; initiated animal protection study (Apr. 2020), Ph 1 (July 2020) and Ph 2 (Nov. 2020) clinical trials in China; FUBITAI has been approved in Hong Kong (Feb.), Macao (March), and Taiwan (Sept.) in 2021. Dr. Hui has directly led the global development and registration of multiple small molecule and biologic anti-cancer drugs including Ixazomib, Isatuximab (anti-CD38) et al. In China, Dr. Hui also has led the development and launch of multiple innovative drugs including Ninlaro, Aatrombopag, FUBITAI, et al. He also witnessed and helped in the development and launch of the first CAR-T therapy Yescarta in China, and the first biosimilar，Rituximab in China. DR. Hui has personally led or participated in over 60 meetings with FDA, CDE (China), EMA, PMDA (Japan) and other Agencies globally. Dr. Hui has over 20 years of experiences in cancer biology, translational oncology and innovative drug development in world's top academic medical centers (National Cancer Institute [NCI], National Cancer Center at Tokyo, Uni. Of Tokyo Hospital) and pharmaceutical companies （Sanofi, Millennium/Takeda, GE Healthcare, Fosun Pharma）. Dr. Hui has granted over 20 international and national scientific awards including the 4th China Translational Medicine Award - International Collaboration Award (2021), 2020 Jishi Award - Top 10 Drug Innovation Scientists, 2020 Jishi Drug Innovation Pioneer Award, Young Investigator Award at the First International Conference on Gastrointestinal Tumorigenesis (1996), Young Investigator Award of the Japanese Society of Gastroenterology and Surgery (1993), et al. Dr Hui has published 100 peer-reviewed articles on top scientific journals including The New England Journal of Medicine, Nature Medicine, The Lancet, Cancer Cell, et al, and authored or co-authored 10 Scientific books including the “Molecular Genetics of Cancer”.